BAP1 promotes viability and migration of ECA109 cells through KLF5/CyclinD1/FGF-BP1

Fengyun Wang1, Ming Luo2, Honglan Qu3 and Yufeng Cheng1

1 Cheeloo College of Medicine, Qilu Hospital, ShanDong University, China
2 The Third Affiliated Hospital of BaoTou Medical College, Mongolia, China
3 Inner Mongolia Agricultural Hospital, YaKeShi, China

Keywords
BAP1; CyclinD1; esophageal carcinoma; FGF-BP; KLF5

Correspondence
Y. Cheng, Department of Radiotherapy, Cheeloo College of Medicine, Qilu Hospital, ShanDong University, No. 107, West Wenhua Road, Li Xia District, Ji Nan City, Shan Dong Province, China
Tel: 0531-82166666
E-mail: qlcyf@sdu.edu.cn

(Received 9 July 2020, revised 28 October 2020, accepted 29 January 2021)
doi:10.1002/2211-5463.13105

More than 40 000 patients worldwide die from esophageal cancer annually. The 5-year survival rate of patients is only ~15–20%, and thus, there is an ongoing need to improve diagnosis and treatment of esophageal cancer. Breast cancer type 1 susceptibility protein (BRCA1)-associated protein (BAP1) is a marker of poor prognosis in several cancers, including uveal melanoma, renal cell carcinoma, cholangiocarcinoma, non-small cell lung cancer, and colorectal cancer. BAP1 mutations are early and rare events in esophageal carcinoma, but the involvement of BAP1 in progression of esophageal carcinoma is unclear. Here, we report that cell proliferation and migration were significantly enhanced in esophageal carcinoma ECA109 cells overexpressing BAP1, while they were diminished upon BAP1 knockdown. In addition, the expression of Krüppel-like factor 5 (KLF5), CyclinD1, and FGF-BP1 was increased by BAP1 overexpression and decreased by BAP1 knockdown. Our data suggest that BAP1 promotes cell proliferation and migration, and enhances the expression of KLF5 and its downstream genes, including CyclinD1 and FGF-BP1, in the esophageal carcinoma cell line ECA109.

Esophageal carcinoma is one of the most serious malignant tumors worldwide. According to statistics, more than 40 000 patients worldwide die from esophageal cancer annually. Esophageal cancer is the eighth most common tumor type and the sixth most common cause of tumor-related deaths worldwide. Based on the 2015 cancer incidence statistics in China, 477 900 new patients were diagnosed with esophageal cancer and 375 000 patients died from esophageal carcinoma [1]. Despite the rapid development of medical technology in the past 10 years, and the significant progress in the diagnosis and treatment of esophageal cancer, the 5-year survival rate of patients is only ~15–20% [2]. Atypical symptoms in the early stages of esophageal cancer and the lack of early warning signs indicate that patients are typically diagnosed with esophageal cancer in the advanced stages. Therefore, studying the pathogenesis of esophageal cancer is important for the early diagnosis and treatment of esophageal cancer.

Breast cancer type 1 susceptibility protein (BRCA1)-associated protein (BAP1) is encoded by the corresponding gene located on chromosome 3p21 and is the only member of the ubiquitin carboxyl-terminal hydrolase family that is localized to the nucleus and has low enzymatic activity [3,4]. BAP1 is closely related to the development of many tumors and mainly acts as a tumor suppressor. The overexpression of BAP1 in the breast cancer MCF-7 cell line inhibits cell colony formation [5]. The overexpression of wild-type BAP1 in lung cancer NCI-H226 cells can significantly inhibit the tumorigenic

Abbreviations
BAP1, breast cancer type 1 susceptibility protein-associated protein; BRCA1, breast cancer type 1 susceptibility protein; FGF-BP1, fibroblast growth factor-binding protein 1; KLF5, Krüppel-like factor 5.
ability of cells in nude mice [6]. Deletions, loss of heterozygosity, missense mutations, and large rearrangements in the BAP1 gene locus have been found in lung and sporadic breast tumors and lung cancer cell lines [7]. In addition, BAP1 can remove the ubiquitination modification of the substrate protein, allowing the substrate to escape the ubiquitin–proteasome degradation pathway and enhance its stability, or affect the functional activity of the substrate, thereby regulating the related signaling [8]. It has been shown that BAP1 promotes the development of breast cancer by releasing the ubiquitin modification of the transcription factor human Krüppel-like factor 5 (KLF5) [9]. However, whether BAP1 regulates KLF5 expression in esophageal cancer is unclear.

We measured the cell proliferation and migration potential of BAP1 overexpression and knockdown systems. We also examined the expression of KLF5 and its downstream target genes CyclinD1 and FGF-BP1 at the mRNA and protein levels.

Materials and methods

Cell line and culture

Cells from ECA109, an esophageal carcinoma cell line, were provided by the Chinese Academy of Sciences (Shanghai, China). ECA109 cells were cultured in RPMI1640 (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% FBS at a constant temperature of 37 °C in a humidity chamber with 5% CO2.

Plasmids, siRNA, and cell transfection

The PcDNA-BAP1 plasmid and empty vector were purchased from OBIO Technology (Shanghai, China), and siRNA-BAP1 or NC was provided by Genepharm (Shanghai, China). The cell culture medium was replaced with serum-free medium 24 h before transfection. Plasmid or siRNA was mixed with serum-free culture medium and maintained for 5 min (mixture A). Lipofectamine 2000 was diluted with serum-free culture medium (mixture B). Mixture B was then added to mixture A and maintained for 10 min (mixture A + B). The cell culture medium was replaced with serum-free medium 24 h before transfection. Plasmid or siRNA was mixed with serum-free culture medium and maintained for 5 min (mixture A). Lipofectamine 2000 was diluted with serum-free culture medium (mixture B). Mixture B was then added to mixture A and maintained for 10 min (mixture A + B). When the cells reached 60% confluence, mixtures A and B were gently added to the cells and the cells were cultured for 24 h. Cells were harvested at 24 h post-transfection and used for further studies. For the BAP1 overexpression system, the empty vector was used as a control. For the BAP1 knockdown system, si-NC was used as a control.

MTT assay

After cell counting, the cell density was adjusted to 1 × 10^5 cells/mL by dilution with serum-free medium. One hundred microliters of cells per well was added to a 96-well plate and cultured for 48 h. For the MTT assay, MTT was dissolved in PBS to a final concentration of 5 mg·mL⁻¹; 10 µL was added to the cells and incubated further for 4 h. The OD value was recorded at 490 nm using a microplate reader (BMG CLARIOstar). The value of the control group was normalized to the average value, and the percentage of survival in other groups was calculated by dividing the ratio by the control average.

Wound-healing assay

A ruler, marker pen, and 6-well plates were prepared and sterilized under ultraviolet light. Horizontal lines were drawn across the wells using a marker pen and ruler on the back of the 6-well plate, and every well was crossed at least five times. Cell suspensions at a concentration of 1 × 10^6 cells were prepared, and 1 × 10^5 cells were added to each well. Vertical lines were drawn using a small pipette and a ruler. Cells were then washed three times with PBS. Floating cells were removed, and serum-free medium was added. The cells were cultured in an incubator at 37 °C with 5% CO2 for 24 h and then photographed.

Real-time quantitative polymerase chain reaction (qRT–PCR)

RNA was extracted from the cells using TRizol Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions, and RNA concentration was measured using a NanoDrop spectrophotometer. Genomic DNA was removed, and reverse transcription of 1 µg RNA was performed using the Transcriptor First-Strand cDNA Synthesis Kit (Roche Applied Science, Basel, Switzerland). The expression levels of all genes, including BAP1, KLF5, CyclinD1, and FGF-BP1, were measured at the mRNA level using the ABI 7500 Fast Real-Time PCR System (Invitrogen). The 2^−ΔΔCt method was used to calculate relative levels.

Western blotting

After the cells were lysed, total protein was extracted. Protein quantification was performed using a BCA Kit, and SDS/PAGE was conducted. The protein from the SDS/PAGE gel was transferred onto a polyvinylidene difluoride membrane. The membrane was blocked using 5% nonfat dried milk for 2 h at room temperature. Primary antibodies were used for treatment at 4 °C overnight, and the membranes were then rinsed three times using PBST. Antibodies against BAP1 (ab245391, 1 : 2000), KLF5 (ab137676, 1 : 1000), CyclinD1 (ab134175, 1 : 10 000), and FGF-BP1 (ab215353, 1 : 500) were provided by Abcam (Cambridge, UK). After washing
again, the membranes were treated with the corresponding secondary antibodies and then washed three times using PBST. The protein bands were visualized using an ECL Kit and photographed.

**Statistical analysis**

Data are presented as average ± SD values. The *t*-test was applied using SPSS version 20.0 (SPSS Inc., IBM, Chicago, IL, USA). A *P*-value < 0.05 (two-sided) suggested a significant difference. Relative expression levels were plotted using GRAPHPAD PRISM 5 software (GraphPad Software; San Diego, CA, USA).

**Results**

**Overexpression of BAP1 enhanced cell proliferation and migration in ECA109 cells**

ECA109 cells were transfected with pcDNA-BAP1 or an empty vector to induce the overexpression of BAP1. The efficiency of transfection results for pcDNA-BAP1 showed that the expression of BAP1 was increased compared with that of the control (Fig. 1A). Western blot analysis of the protein expression level of BAP1 confirmed the overexpression of BAP1 in the pcDNA-BAP1 group (Fig. 1B). The MTT assay was used to evaluate cell proliferation, and the results revealed that cell proliferation was notably enhanced in ECA109 cells transfected with pcDNA-BAP1 compared to those transfected with the empty vector (Fig. 1C). Cell migration was then evaluated by the wound-healing assay, and the results suggested that the migration of ECA109 cells transfected with pcDNA-BAP1 increased notably compared with that in the control (Fig. 1D).

**Knockdown of BAP1 impeded cell proliferation and migration in ECA109 cells**

To further examine the effect of BAP1 on cell proliferation and migration, knockdown of BAP1 was achieved using siRNA-BAP1. The efficiency of
transfection results for siRNA-BAP1 showed that the expression of BAP1 was reduced in the siRNA-BAP1 group compared with the NC group (Fig. 2A, B). Similar to the overexpression of BAP1, cell proliferation and migration were measured by MTT and wound-healing assays in the BAP1 knockdown system. The results showed that cell proliferation and migration in ECA109 cells transfected with siRNA-BAP1 were notably inhibited compared with that in the NC group (Fig. 2C, D).

BAP1 expression affected KLF5 and its downstream genes, including CyclinD1 and FGF-BP1

Qin et al. [9] reported that BAP1 interacts directly with KLF5 in breast cancer and that KLF5 is stabilized by deubiquitinase BAP1. In our study, we investigated whether KLF5 expression would change when the expression of BAP1 increased or reduced. As expected, the expression of KLF5 was enhanced in the BAP1 overexpression system compared with that in the control (Fig. 3A). KLF5 mRNA levels were also significantly reduced in ECA109 cells transfected with siRNA-BAP1 compared with those in the NC group (Fig. 3A). Interestingly, we found that the expression of downstream genes, KLF5, CyclinD1, and FGF-BP1, was positively regulated by the expression of KLF5. As shown in Fig. 3A, the expression of CyclinD1 and FGF-BP1 reduced or increased significantly in the BAP1 knockdown or overexpression systems, respectively. In addition, the expression of KLF5, CyclinD1, and FGF-BP1 was further verified at the protein level and showed similar tendencies to the mRNA expression levels (Fig. 3B).

Discussion

The incidence of esophageal cancer in China is considerably high, second only to that of gastric cancer [10]. Particularly in rural areas of China, esophageal carcinoma has one of the highest incidences among all
tumor types [11]. The early surgical resection rate of esophageal cancer is 100%, and the 5-year survival rate is more than 90%. However, most patients are diagnosed with esophageal cancer in the middle and advanced stages, and the 5-year survival rate after surgical resection is still relatively low. Therefore, the identification of markers for the early diagnosis and prognosis of esophageal carcinoma is of great significance in clinical practice.

In recent years, BAP1 has been studied extensively in various cancers. Luchini et al. first reported a meta-relationship between BAP1 deletion and the diagnoses and prognoses of various cancer types, and confirmed that BAP1 is a marker of poor prognosis in diverse cancer types, including uveal melanoma, renal cell carcinoma, cholangiocarcinoma, non-small cell lung cancer, and colorectal cancer [12]. Inactivating BAP1 mutants were found in two patients with uveal melanoma by exon capture and large-scale sequencing, and BAP1 mutants were also found in 25 (45%) of 55 additional cases of uveal melanoma [13]. Andrici et al. suggested that the deletion of BAP1 is a diagnostic marker of mesothelioma in effusion cytology [14]. However, BAP1 has rarely been studied in esophageal cancer. BAP1 mutations have been reported as early and rare events in esophageal cancer [15].

In this study, we aimed to explore the function of BAP1 in the pathogenesis of esophageal squamous cell carcinoma. Qin et al. [9] found that BAP1 promotes proliferation and metastasis in the breast cancer cell line MDA-MB-468. In our study, BAP1 was overexpressed and knocked down in vitro, and the proliferation and migration abilities of the cells were examined. MTT and wound-healing assay results showed that the overexpression of BAP1 significantly enhanced cell proliferation and migration, which is consistent with the results reported by Qin et al. [9].

In our study for determining the mechanism underlying BAP1 function, we occasionally observed that KLF5 expression correlated positively with BAP1 expression. Both mRNA expression and protein expression of KLF5 increased significantly in the BAP1 overexpression system, whereas the expression was impaired in the BAP1 knockdown system. KLF5 belongs to the SP/KLF transcription factor family and has three common C2H2-type zinc finger structures at the carboxy terminus. Studies have shown that KLF5 can regulate the expression of a variety of genes, including CyclinD1, inducible nitric oxide synthase, plasminogen activator inhibitor 1, TGF-β, and VEGF receptor genes [16]. In addition, Zheng et al. [17] have reported that KLF5 promotes breast cell proliferation by upregulating the transcription of fibroblast growth factor-binding protein 1 (FGF-
BAP1). We hypothesized that BAP1 expression may also affect target genes downstream of KLF5, such as CyclinD1 and FGF-BP1. Next, we examined the mRNA and protein expression levels of CyclinD1 and FGF-BP1 genes in the BAP1 overexpression and knockdown systems. We found that CyclinD1 and FGF-BP1 were upregulated when BAP1 was overexpressed, while the expression levels of CyclinD1 and FGF-BP1 were significantly reduced in the BAP1 knockdown system, which is consistent with the results reported by Zheng et al. [17].

Conclusion

The overexpression or knockdown of BAP1 enhanced or impaired cell proliferation and migration, respectively, in ECA109 cells. Additionally, the expression of KLF5, CyclinD1, and FGF-BP1 altered correspondingly. We concluded that BAP1 might promote cell proliferation and migration via KLF5/CyclinD1/FGF-BP1 in ECA109 cells.

Acknowledgement

This work was supported by grants from the Taishan Scholars of Shandong Province (ts20190973).

Conflict of interest

The authors declare no conflict of interest.

Data Accessibility

The research data are available from the corresponding author upon reasonable request.

Author contributions

FW and YC conceived and designed the project. ML conducted the experiments. HQ analyzed and interpreted the data. FW wrote the manuscript.

References

1 Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66: 115–132.
2 Pennathur A, Gibson MK, Jobe BA and Luketich JD (2013) Oesophageal carcinoma. Lancet 381, 400–412.
3 Sahtoe DD, van Dijk WJ, Ekkebus R, Ovaa H and Sixma TK (2016) BAP1/ASXL1 recruitment and activation for H2A deubiquitination. Nat Commun 7, 10292.
4 Larsen CN, Krantz BA and Wilkinson KD (1998) Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases. Biochemistry 37, 3358–3368.
5 Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA, Ishov AM, Tommerup N, Vissing H, Sekido Y et al. (1998) BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 16, 1097–1112.
6 Ventii KH, Devi NS, Friedrich KL, Chernova TA, Tighiouart M, Van Meir EG and Wilkinson KD (2008) BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res 68, 6953–6962.
7 Mani A and Gelmann EP (2005) The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 23, 4776–4789.
8 Machida YJ, Machida Y, Vashisht AA, Wohlschlegel JA and Dutta A (2009) The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. J Biol Chem 284, 34179–34188.
9 Qin J, Zhou Z, Chen W, Wang C, Zhang H, Ge G, Shao M, You D, Fan Z, Xia H et al. (2015) BAP1 promotes breast cancer cell proliferation and metastasis by deubiquitinating KLF5. Nat Commun 6, 4871.
10 Kaz AM and Grady WM (2014) Epigenetic biomarkers in esophageal cancer. Cancer Lett 342, 193–199.
11 Zeng H, Zheng R, Zhang S, Zuo T, Xia C, Zou X and Chen W (2016) Esophageal cancer statistics in China, 2011: estimates based on 177 cancer registries. Thorac cancer 7, 232–237.
12 Luchini C, Veronese N, Yachida S, Cheng L, Nottegar A, Stubbs B, Solmi M, Capelli P, Pea A, Barbareschi M et al. (2016) Different prognostic roles of tumor suppressor gene BAP1 in cancer: a systematic review with meta-analysis. Genes Chromosomes Cancer 55, 741–749.
13 Harbour JW, Onken MD, Roberson EDO, Duan S, Cao L, Worley LA, Council ML, Matatall KA, Helms C and Bowcock AM (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330, 1410–1413.
14 Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S et al. (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43, 1022–1025.
15 Loeber H, Waldschmidt D, Kuetting F, Schallenberg S, Zander T, Bollschweiler E, Hoelscher A, Weckermann K, Plum P, Alakus H et al. (2017) Somatic BRCA1-associated protein 1 (BAP1) loss is an early and rare event in esophageal adenocarcinoma. Mol Clin Oncol 7, 225–228.
16 Nagai R, Suzuki T, Aizawa K, Shindo T and Manabe I (2005) Significance of the transcription factor KLF5 in...
cardiovascular remodeling. *J Thromb Haemost* **3**, 1569–1576.

17 Zheng H-Q, Zhou Z, Huang J, Chaudhury L, Dong J-T and Chen C (2009) Krüppel-like factor 5 promotes breast cell proliferation partially through upregulating the transcription of fibroblast growth factor binding protein 1. *Oncogene* **28**, 3702–3713.